PAVmed Inc. reports recurring business updates as a diversified commercial-stage medical technology company operating across medical devices, diagnostics and digital health. Company updates commonly address financial results, capital-structure actions, medical device portfolio development and subsidiary activity.
News also covers Lucid Diagnostics, PAVmed's commercial-stage cancer prevention diagnostics subsidiary, including EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device activity for patients at risk of esophageal precancer and cancer. Other recurring subjects include Veris Health digital health programs, the Veris Cancer Care Platform, implantable physiological monitor development and PAVmed's endoscopic esophageal imaging technology through Octeris.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced a strategic spin-off of its subsidiary Lucid Diagnostics, aiming to enhance its commercial potential through an IPO or SPAC merger. This decision follows a robust financial position bolstered by raising over $30 million, which supports Lucid's new multi-channel commercialization initiative for the EsoGuard Esophageal DNA Test. Key highlights include a strengthened sales team and a rebound in EsoGuard testing volume, although challenges remain with ongoing clinical studies and insurance coverage determinations.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced a change in the time of its business update conference call to 8:30 AM EST on February 22, 2021. The call will feature Stanley Lapidus, a medical diagnostics pioneer, along with PAVmed's CEO Lishan Aklog and CFO Dennis McGrath. Mr. McGrath will provide a financial update, while Dr. Aklog will discuss Lucid Diagnostics' growth strategy. PAVmed is focused on innovative medical devices, aiming for rapid commercialization and addressing critical clinical needs across various divisions.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced the successful U.S. patient procedure using its CarpX device for carpal tunnel release, a significant advancement in minimally invasive surgery. Unlike traditional methods with longer recovery times, the patient returned to work as a truck driver within one week. The company aims to reduce overall healthcare costs and treat more patients suffering from carpal tunnel syndrome, with the CarpX device offering a market opportunity estimated at $1 billion in the U.S. This commercial launch marks a critical step in establishing CarpX as a new standard of care.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced a business update conference call on February 22, 2021, at 4:30 p.m. ET. CEO Lishan Aklog will present the company's growth strategy and milestones, while CFO Dennis McGrath will discuss Q4 2020 financial results. Interested listeners can access the call via phone or webcast. PAVmed is a multi-product, commercial-stage medical device company with a diverse pipeline addressing unmet clinical needs across various sectors.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) has closed a registered direct offering of 6 million shares at $2.24 each, generating approximately $12.4 million in net proceeds. These funds will be allocated for working capital, general corporate purposes, and to repay part of the company’s outstanding convertible notes. The offering was conducted under a shelf registration statement and was facilitated by Maxim Group LLC as the sole placement agent.
PAVmed Inc. has announced a registered direct offering of 6.0 million shares of common stock, priced at $2.24 each, to raise approximately $13.4 million in gross proceeds. The net proceeds expected are around $12.4 million after deducting fees. The offering is anticipated to close on or about January 8, 2021. Maxim Group LLC is the placement agent for this offering, which is backed by a shelf registration statement declared effective by the SEC in September 2020. This move intends to enhance its pipeline strategy and advance innovative medical products.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) has completed a registered direct offering of approximately 5.1 million shares of common stock at $1.60 per share, generating approximately $7.4 million in net proceeds after expenses. The funds will be used for working capital, corporate purposes, and to repay some outstanding convertible notes. This offering was conducted under a previously effective shelf registration statement. Maxim Group LLC served as the lead placement agent.
PAVmed Inc. has announced a registered direct offering of approximately 5.1 million shares of common stock at $1.60 per share, raising gross proceeds of $8.1 million. After estimated expenses, net proceeds are expected to be around $7.4 million. The offering is anticipated to close on December 22, 2020, pending customary conditions. Maxim Group LLC and Lake Street Capital Markets LLC are acting as placement agents. This move is part of PAVmed's strategy to enhance its diversified product pipeline, which addresses unmet clinical needs across various medical fields.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced a registered direct offering of 5.6 million shares of common stock at $1.60 per share, generating approximately $8.9 million in gross proceeds. After fees and expenses, the net proceeds are estimated at $8.3 million. The offering is set to close around December 15, 2020, pending customary conditions. Maxim Group LLC serves as the lead placement agent. The offering follows a shelf registration statement declared effective by the SEC on September 17, 2020.
PAVmed Inc. (PAVM, PAVMZ) provided a business update and financial results for Q3 2020, highlighting accelerated commercial activity for its products. CEO Lishan Aklog noted significant growth in EsoGuard® testing and EsoCheck® procedures, driven by new CMS payment determinations effective January 1, 2021, setting the price at $1,938.01. The company also expanded its sales team and secured multiple patents. Despite a GAAP net loss of $5.6 million for Q3, cash reserves increased to $8.3 million. Plans for European commercialization and upcoming clinical trials were discussed.